Investing.com - Treace Medical Concepts (NASDAQ: TMCI) reported fourth quarter EPS of $-0.10, $0.01 worse than the analyst estimate of $-0.09. Revenue for the quarter came in at $62.2M versus the consensus estimate of $60.57M.
Guidance
Treace Medical Concepts sees FY 2024 revenue of $220.00M-$225.00M versus the analyst consensus of $223.10M.
Treace Medical Concepts's stock price closed at $14.38. It is up 54.46% in the last 3 months and down -32.99% in the last 12 months.
Treace Medical Concepts saw 0 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Treace Medical Concepts's stock price’s past reactions to earnings here.
According to InvestingPro, Treace Medical Concepts's Financial Health score is "fair performance".
Check out Treace Medical Concepts's recent earnings performance, and Treace Medical Concepts's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar